Envestnet Asset Management
RPRX icon

Envestnet Asset Management’s Royalty Pharma RPRX Stock Holding History

Envestnet Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.8M Buy
513,096
+17,204
+3% +$895K 0.01% 1182
2026
Q1 		$23.8M Buy
495,892
+40,141
+9% +$1.76M 0.01% 1234
2025
Q4 		$17.6M Buy
455,751
+18,300
+4% +$698K 0.01% 1292
2025
Q3 		$15.4M Buy
437,451
+339,839
+348% +$12.3M ﹤0.01% 1467
2025
Q2 		$3.52M Sell
97,612
-6,250
-6% -$207K ﹤0.01% 2452
2025
Q1 		$3.23M Buy
103,862
+37,102
+56% +$1.18M ﹤0.01% 2422
2024
Q4 		$1.7M Sell
66,760
-763
-1% -$20.2K ﹤0.01% 2802
2024
Q3 		$1.91M Sell
67,523
-9,102
-12% -$252K ﹤0.01% 2688
2024
Q2 		$2.02M Sell
76,625
-12,114
-14% -$336K ﹤0.01% 2590
2024
Q1 		$2.7M Buy
88,739
+49,256
+125% +$1.45M ﹤0.01% 2381
2023
Q4 		$1.11M Buy
39,483
+18,139
+85% +$498K ﹤0.01% 2868
2023
Q3 		$579K Buy
21,344
+5,858
+38% +$174K ﹤0.01% 3171
2023
Q2 		$476K Sell
15,486
-339
-2% -$11.5K ﹤0.01% 3235
2023
Q1 		$570K Buy
15,825
+2,899
+22% +$107K ﹤0.01% 3052
2022
Q4 		$511K Buy
12,926
+428
+3% +$17.9K ﹤0.01% 3087
2022
Q3 		$502K Buy
12,498
+2,371
+23% +$101K ﹤0.01% 3019
2022
Q2 		$426K Buy
10,127
+1,603
+19% +$65.7K ﹤0.01% 3145
2022
Q1 		$332K Buy
8,524
+2,176
+34% +$85.4K ﹤0.01% 3389
2021
Q4 		$253K Buy
+6,348
New +$247K ﹤0.01% 3510

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Envestnet Asset Management's RPRX Position: Q2 2026 in Review

Envestnet Asset Management increased its Royalty Pharma (RPRX) stake by 3.5% in Q2 2026, buying an estimated $895K and bringing the position to 513,096 shares worth $28.8M. The position accounts for 0.01% of the portfolio, ranked #1182.

Envestnet Asset Management first reported a position in RPRX in Q4 2021 and has held it in 19 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Envestnet Asset Management held 513,096 shares of Royalty Pharma worth $28.8M as of Q2 2026.
  • Envestnet Asset Management bought 17,204 Royalty Pharma shares in Q2 2026, an estimated $895K.
  • Royalty Pharma made up 0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #1182 holding.
  • Envestnet Asset Management first reported a position in Royalty Pharma in Q4 2021 and has held it in 19 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.